Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > Exploring DNA Repair Pathways as Targets for Cancer Therapy

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Exploring DNA Repair Pathways as Targets for Cancer Therapy

Target DNA repair for Cancer Therapy

12 Feb 2015 - 15 Feb 2015

Cancun, Mexico

Synopsis

The first in the series of the Exploring DNA Repair Pathways as Targets for Cancer Therapy Fusion conferences. 

Defect in DNA damage repair and checkpoint control is the underlying mechanism for tumorigenesis, since it allows the accumulation of multiple genetic alternations, which are essential for the initiation of tumorigenesis. This has been clearly illustrated to be the cause of several human cancer-prone syndromes and also revealed by recent human genome studies. On the other hand, defective DNA repair and checkpoint activation also make cancer cells more vulnerable for particular DNA damaging agents or inhibitors that specifically disrupt some of these checkpoint pathways. With the increasing understanding of defects in DNA repair and checkpoint control in tumorigenesis, there are extensive interests in exploring these deficiencies, especially taking advantage of the synthetic lethality concept and targeting particular DNA repair and checkpoint pathways for cancer therapy. The purpose of this conference is to bring together basic, translational and clinical investigators and discuss the current and future directions, opportunities and obstacles in the development of these anti-cancer modalities and how to best apply these concepts in clinical practice.

Key Sessions

  • Highlight recent advances in the field of DNA damage repair
  • Identify novel targets in DNA repair and checkpoint pathways
  • Explore the concept of synthetic lethality for cancer treatment
  • Assess the therapeutic potential of new anti-cancer modalities
  • Learn mechanisms of therapeutic resistance and ways to improve cancer therapy

Target Audience

This conference explores topics that should appeal to basic, translational and clinical investigators as well as clinicians ranging from academics to industry. The audience will benefit greatly from the interactions with experts in the fields of DNA damage response, drug development and clinical trials.

2015 DNA Poster Prize

The conference chairs will be awarding 3 poster prizes for the best poster display and presentation. To be in with a chance of winning, submit your poster by 21 November 2014. The winners will be selected shortly after the Poster Session and each winner will receive a $250 cheque! 

Confirmed Plenary Speakers

Dr. Giulio Draetta
The University of Texas MD Anderson Cancer Center
Professor Thomas Helleday

Karolinska Institutet
Dr. Maria Jasin
Memorial Sloan Kettering Cancer Center
Dr. Andre Nussenzweig
National Cancer Institute
Professor John Tainer
Scripps Research Institute 

Confirmed Invited Speakers

Prof. Chris Bakkenist
University of Pittsburgh School of Medicine
Dr. Eric Brown
University of Pennsylvania School of Medicine
Dr. Phil Connell

The University of Chicago Medicine
Dr. David Ferguson 
University of Michigan
Dr. Susana Gonzalo 
Saint Louis University
Dr. Roger Greenberg
Abramson Family Cancer Research Institute 
Professor Reuben Harris
University of Minnesota
Professor Wolf-Dietrich Heyer
University of California 
Dr. Karen Knudsen
Kimmel Cancer Center
Dr. Kyle Miller 
University of Texas Austin
Dr. Jac A. Nickoloff 
Colorado State University
Professor Jeffrey Parvin 
Ohio State University
Dr. Tanya Paull
The University of Texas at Austin
Dr. Bill Plunkett
The University of Texas MD Anderson Cancer Center
Dr. Simon Powell
Memorial Sloan Kettering Cancer Center
Dr. Jorge S. Reis-Filho
Memorial Sloan Kettering Cancer Center
Dr. Binghui Shen
City of Hope
Dr. Barry Sleckman

Washington University - School of Medicine
Dr. Robert Sobol
University of Pittsburgh
Dr. Henning Willers
Massachusetts General Hospital
Dr. Zhongshen You
University of Washington
Dr. Xiaochun Yu
University of Michigan
Dr. Lee Zou
Harvard/MGH Cancer Center 

Sponsors

Sponsors

Report

This new major conference on Target DNA repair for Cancer Therapy took place in Cancun, Mexico from 12 to 15 February 2015. The significance of this meeting was marked by euthasitic attendees from many leaders in the field of DNA damage repair pathways who are interested in identifying new targets and strategies for improving cancer therapy by targeting distinct DNA repair pathways.

The meeting was chaired by Dr. Helen Piwnica-Worms (Vice Provost, Science, The University of Texas MD Anderson Cancer Center) and Dr. Junjie Chen (Professor and Chain, Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center).

Faculty included Dr. Giulio Draetta (The University of Texas MD Anderson Cancer Center), Dr. Maria Jasin (Memorial Sloan Kettering Cancer Center), Dr. Andre Nussenzweig (National Cancer Institute), Professor John Tainer (Scripps Research Institute), Prof. Chris Bakkenist (University of Pittsburgh School of Medicine), Dr. Eric Brown (University of Pennsylvania School of Medicine), Dr. Phil Connell (The University of Chicago Medicine), Dr. David Ferguson (University of Michiga), Dr. Susana Gonzalo (Saint Louis University), Dr. Roger Greenberg (Abramson Family Cancer Research Institute), Professor Wolf-Dietrich Heyer (University of California), Dr. Karen Knudsen (Kimmel Cancer Center), Dr. Kyle Miller (University of Texas Austin), Dr. Jac A. Nickoloff (Colorado State University), Professor Jeffrey Parvin (Ohio State University), Dr. Tanya Paull (The University of Texas at Austin), Dr. Bill Plunkett (The University of Texas MD Anderson Cancer Center), Dr. Simon Powell (Memorial Sloan Kettering Cancer Center), Dr. Jorge S. Reis-Filho (Memorial Sloan Kettering Cancer Center), Dr. Binghui Shen (City of Hope), Dr. Barry Sleckman (Washington University, School of Medicine< Dr. Robert Sobol (University of Pittsburgh), Dr. Henning Willers (Massachusetts General Hospital), Dr. Zhongshen You (University of Washington), Dr. Xiaochun Yu (University of Michigan), and Dr. Lee Zou (Harvard/MGH Cancer Center)

The meeting highlighted several exciting areas in the field of DNA damage response, which include 1) repair pathway choices and therapeutics outcomes, 2) new therapeutic targets in DNA repair, 3) ongoing clinical trials targeting DNA repair pathways and DNA damage checkpoints. Exciting presentations from basic scientists, clinicians and translational experts presented multitude of new strategies for cancer therapy, which range from concepts, leading compounds, to early clinical trials. The meeting was highly interactive and generated healthy discussions about current and future directions of the field. Novel ideas were exchanged and collaborations were established, which focus on distinct repair pathways and components involved in DNA double strand breaks, novel functions of repair proteins, checkpoint regulators, and chromatin modulators, and key signaling pathways and kinases that are existing and potential targets for cancer therapy.

The participation of internationally renowned leaders in the field of DNA damage response together with the excitement of new drugs like PARP inhibitors and checkpoint kinase inhibitors that hold great promise in clinical trials created a supportive meeting environment. The investigators were eager to work together to address several key questions in the field. It was agreed that the timing is right for a conference like this that helps to accelerate the development of new concepts and agents in DNA repair for cancer treatment.  

_____________________________________

The meeting was expertly organized and supported by Fusion Conferences, Ltd.  The University of Texas MD Anderson Cancer Center generously and enthusiastically supported the meeting in many ways and the generous support of Cell Signaling Technology is also gratefully appreciated.

Programme

Thursday 12th February 2015

12:00 – 15:00

Registration

13:00 -14:15

Welcome Lunch
*Kalmia Buffet Restaurant
*

Repair pathway choices and therapeutic outcomes (1)
Session Chair:  Roger Greenberg

15:30 – 15:45

Opening Speech

15:45 – 16:30

Andre Nussenzweig

National Institutes of Health

TUMOR PROMOTING ROLE OF THE DNA DAMAGE RESPONSE

16:30 – 17:00

Barry Sleckman
Washington University School of Medicine

TARGETING ABERRANT DNA DOUBLE STRAND BREAK REPAIR IN G1-PHASE CELLS

17:00 – 17:30

David Ferguson
The University of Michigan

THE MRN COMPLEX AS A POTENTIAL TARGET FOR CANCER THERAPY

17:30 – 18:00

Refreshments

Repair pathway choices and therapeutic outcomes (2)
Session Chair:  Barry Sleckman

18:00 – 18:30

Simon Powell
Memorial Sloan Kettering Cancer Center

BACK-UP PATHWAYS FOR BRCA1-BRCA2 MEDIATED HOMOLOGOUS RECOMBINATION

18:30 – 19:00

Junjie Chen
The University of Texas MD Anderson Cancer Center

MULTIPLE REPAIR PATHWAYS DETERMINE THERAPEUTIC OUTCOMES

19:00 – 19:30

Roger Greenberg
University of Pennsylvania

GENETIC INTERACTIONS WITHIN THE BRCA TUMOR SUPPRESSOR NETWORK

19:30 – 20:00

Ralph Scully
Beth Israel Deaconess Med Ctr

RECOMBINATION CONTROL BY BRCA1 AND BRCA2 AT STALLED MAMMALIAN REPLICATION FORKS: OPPORTUNITIES FOR THERAPY

20:00 – 20:15

Richard Pomerantz
Temple University

TARGETED KILLING OF BRCA DEFICIENT CELLS BY A SMALL-MOLECULE INHIBITOR OF RAD52

20:15 – 20:30

Panel Discussion PM

20:30

Dinner at Leisure & Free Time

Friday 13th February 2015

07:00 -08:30

Breakfast

Emerging therapeutic targets and clinical trials for cancer therapy
Session Chair: Karen Knudsen

08:30 – 09:15

Thomas Helleday
Karolinska Institutet

TARGETING MTH1 FOR TREATMENT OF CANCER

 

09:15 – 09:45

Wolf-Dietrich Heyer
University of California, Davis

RECOMBINATIONAL DNA REPAIR: FROM BASIC MECHANISM TO CANCER THERAPY

09:45 – 10:15

Philip Connell
University of Chicago

DEVELOPMENT OF RAD51-MODULATING COMPOUNDS AS POTENTIAL ONCOLOGY DRUGS

10:15 – 10:45

Robert W. Sobol
University of South Alabama Mitchell Cancer Institute

TARGETING ADP-RIBOSYLATION PROTEINS IN GLIOMA STEM CELLS

10:45 -11:00

Kent W Mouw

Dana-Farber Cancer Institute

ERCC2 MUTATIONS CONFER LOSS OF NUCLEOTIDE EXCISION REPAIR CAPACITY AND PREDICT RESPONSE TO CISPLATIN-BASED CHEMOTHERAPY IN UROTHELIAL CARCINOMA

11:00 – 11:15

Refreshments

11:15 – 11:45

Jorge Reis-Filho
Memorial Sloan-Kettering Cancer Center

 

11:45 – 12:15

Henning Willers
Massachusetts General Hospital

TARGETING DNA DOUBLE-STRAND BREAK INDUCTION AND REPAIR IN
GENOTYPE-DEFINED CANCERS

12:15 – 12:30

Bernd Kaina
University Medical Center, Mainz

SURVIVAL AND DEATH STRATEGIES OF GLIOMA AND MALIGNANT MELANOMA CELLS EXPOSED TO ALKYLATING ANTICANCER DRUGS

12:30 – 12:45

Panel Discussion AM

12:45 – 16:00

Lunch at Leisure & Free Time

Multiple targets and cellular processes involved in cancer development and treatment
Session Chair: Markus Löbrich

16:00 – 16:30

Tanya Paull
The University of Texas at Austin

REGULATION OF SAE2 AND CTIP ACTIVITY THROUGH PHOSPHORYLATION

 

16:30 – 17:00

Binghui Shen
Beckman Research Institute of City of Hope

ALPHA-SEGMENT ERROR EDITING BY THE MAMMALIAN FEN1/MUTSΑ FUNCTIONAL COMPLEX

 

17:00 – 17:15

Katharina Schlacher
MD Anderson Cancer Center

RECRUITMENT OF 53BP1 FOR REPLICATION FORK RESTART AND STABILITY DEPENDS UPON A PHOSPHATASE-INDEPENDENT PTEN ACTIVITY

17:15 – 17:30

Gregory C. Stachelek
Yale University School of Medicine

ARYL SULFONAMIDES ARE A NOVEL CLASS OF HOMOLOGY-DEPENDENT DNA REPAIR INHIBITORS WITH ANTINEOPLASTIC ACTIVITY

17:30 – 18:00

Susana Gonzalo
Saint Louis University School of Medicine

VITAMIN D RECEPTOR MODULATES DNA REPAIR: IMPLICATIONS FOR BREAST CANCER AND PROGERIA

18:00 – 18:30

Refreshments

18:30 – 19:15

Giulio Draetta
The University of Texas MD Anderson Cancer Center

 

19:15 – 19:45

Kyle Miller
University of Texas at Ausin

ATM LINKS ENDOGENOUS OXIDATIVE STRESS TO TUMOR PROMOTION

19:45 – 20:00

Srividya Bhaskara
Huntsman Cancer Institute

HISTONE DEACETYLASES 1,2: GUARDIANS OF GENOME STABILITY

 

20:00 – 20:15

Sergio Ruiz

CNIO

REPLICATIVE STRESS DURING SOMATIC CELL REPROGRAMMING

20:15 – 20:30

Panel Discussion PM

20:30

Dinner at Leisure & Free Time

Saturday 14th February 2015

07:00 – 08:30

Breakfast

Current and potential therapeutic targets in DNA repair pathways
Session Chair: Wolf-Dietrich Heyer

08:30 – 09:15

John Tainer
Lawrence Berkeley National Laboratory

ZEROING IN ON MASTER KEYS TO EXCEPTIONAL RESPONDERS FOR CANCERS

09:15 – 09:45

Jean Gautier
Columbia University

Mechanisms of MYC-driven genomic instability

09:45 – 10:00

Bipasha Mukherjee
UT Southwestern Medical Center at Dallas

Inhibition of DNA Double-Strand Break Repair by A Dual PI3K/mTOR Inhibitor as a Strategy for Radiosensitization of Glioblastoma

 

10:00 – 10:30

Zhongsheng You
Washington University School of Medicine

COORDINATED REGULATION OF EXO1 IN DNA END RESECTION AND ITS IMPLICATIONS IN CANCER THERAPY

10:30 – 10:45

Anand Jeyasekharan

Cancer Science Institute of Singapore

BRCA2-RAD51 NUCLEAR EXPORT; FROM MOLECULAR MECHANISM TO A BIOMARKER OF HOMOLOGOUS RECOMBINATION DEFICIENCY

10:45 – 11:00

Sharon Cantor
University of Massachusetts Medical School

A NOVEL MECHANISM OF THERAPY RESISTANCE IN BRCA2-MUTANT CELLS

11:00 – 11:30

Refreshments

11:30 – 12:00

Karen Knudsen
Thomas Jefferson University

TARGETING HORMONE-DNA REPAIR CROSSTALK IN PROSTATE CANCER: MECHANISMS AND IMPLICATIONS FOR THERAPEUTIC INTERVENTION

12:00 – 12:30

Bill Plunkett
The University of Texas MD Anderson Cancer Center

MECHANISM-BASED THERAPEUTIC STRATEGY TO TARGET A RECURRENT GENETIC LESION IN THE HOMOLOGOUS RECOMBINATION REPAIR PATHWAY

12:30 – 12:45

Panel Discussion

12:45 – 16:30

Lunch at Leisure & Free Time

Checkpoint kinases as therapeutic targets
Session Chair: Xiaochun Yu

16:30 – 17:00

Helen Piwnica-Worms
The University of Texas MD Anderson Cancer Center

DNA DAMAGE, CHECKPOINT SIGNALING AND THERAPEUTIC OPPORTUNITIES

17:00 – 17:30

Eric Brown
University of Pennsylvania

ATR INHIBITION AS A BROAD SPECTRM CANCER THERAPY TARGETED BY COMMON CANCER-ASSOCIATED MUTATIONS

17:30 – 18:00

Lee Zou
Massachusetts General Hospital

ALTERNATIVE LENGTHENING OF TELOMERES RENDERS CANCER CELLS HYPERSENSITIVE TO ATR INHIBITORS

18:00 – 18:15

Xuetong Shen
The University of Texas MD Anderson Cancer Center

REGULATION OF KEY CHECKPOINT KINASES BY ATP-DEPENDENT CHROMATIN REMODELING COMPLEXES – NOVEL PATHWAYS TO TARGET IN CANCER

 

18:15 – 18:45

Christopher Bakkenist
University of Pittsburgh School of Medicine

INHIBITION OF ATR KINASE ACTIVITY FOR THE TREATMENT OF LUNG CANCER

18:45 – 19:00

Panel Discussion

19:00 – 20:00

Poster Session & Cocktails

20:15 – 23:00

Gala Night, Group Photo & Poster Awards

*Lower Pool Deck*

Sunday 15th February 2015

07:00 -08:30

Breakfast

DNA double-strand repair pathways in response to anti-cancer therapies (1)
Session Chair: Sharon Cantor

08:30 – 09:15

Maria Jasin
Memorial Sloan-Kettering Cancer Center

 

09:15 -09:45

Xiaochun Yu
University of Michigan

NOVEL POLY(ADP-RIBOSE) BINDING DOMAINS AND POLY(ADP-RIBOSE)-DEPENDENT SIGNAL TRANSDUCTION

09:45 – 10:15

Jeffrey Parvin
Ohio State University

BRCA1, 53BP1, AND SUMO FACTORS IN DNA DOUBLE-STRAND BREAK REPAIR

10:15 – 10:45

Jac Nickoloff
Colorado State University

METNASE AND EEPD1:  TWO NUCLEASES THAT REGULATE DSB REPAIR, REPLICATION STRESS RESPONSES AND GENOME STABILITY

 

10:45 – 11:15

Refreshments

DNA double-strand repair pathways in response to anti-cancer therapies (2)
Session Chair: Jeffrey Parvin

11:15 – 11:30

Junran Zhang
Case Western Reserve University

RNF126 PROMOTES HOMOLOGOUS RECOMBINATION VIA REGULATING E2F1-MEDIATED BRCA1 EXPRESSION

11:30 – 11:45

Markus Löbrich
Darmstadt University of Technology

NEK1 PHOSPHORYLATES RAD54 TO PROMOTE HOMOLOGOUS RECOMBINATION

11:45 – 12:00

Tomasz Skorski

Temple University School of Medicine

GENE EXPRESSION AND MUTATION ANALYSIS (GEMA) –GUIDED PRECISION MEDICINE TARGETING PARP1 TO INDUCE SYNTHETIC LETHALITY IN DNA-PK –DEFICIENT QUIESCENT AND BRCA -DEFICIENT PROLIFERATING LEUKEMIA STEM AND PROGENITOR CELLS

12:00 – 12:15

Panel Discussion

12:15 – 12:30

Closing Remarks

Speakers

Plenary Speakers

Invited Speakers

  • Dr. Barry Sleckman
    Professor of Pathology and Immunology, Washongton University School of Medicine
  • Dr. Zhongsheng You
    Assistant Professor, Washington University School of Medicine
  • Dr. Roger Greenberg
    Associate Professor, University of Pennsylvania
  • Dr. Xiaochun Yu
    Associate Professor of Internal Medicine, University of Michigan
  • Prof. Dr. Wolf-Dietrich Heyer
    Professor and Chair, University of California, Davis
  • Dr. Philip Connell
    Associate Professor, University of Chicago
  • Dr. Jorge Reis-Filho
    Attending, Memorial Sloan-Kettering Cancer Center
  • Prof. Tanya Paull
    Professor, The University of Texas at Austin
  • Dr. Eric Brown
    Associate Professor of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania
  • Prof. David Ferguson
    Associate Professor, The University of Michigan
  • Prof. Jeffrey Parvin
    Professor, Ohio State University
  • Prof. Jac Nickoloff
    Professor and Head, Colorado State University
  • Dr. Kyle Miller
    Assistant Professor, University of Texas at Ausin
  • Dr. Simon Powell
    Radiation Oncology and Molecular Biology, Memorial Sloan Kettering Cancer Center
  • Dr. Susana Gonzalo
    Associate Professor, Saint Louis University School of Medicine
  • Dr. Henning Willers
    Associate Professor, Massachusetts General Hospital
  • Dr. Binghui Shen
    Professor and Chair, Radiation Biology, Beckman Research Institute of City of Hope
  • Prof. Karen Knudsen
    Sidney Kimmel Cancer Center, TJU, Thomas Jefferson University
  • Prof. Christopher Bakkenist
    Associate Professor, University of Pittsburgh School of Medicine
  • Prof. Bill Plunkett
    Professor, Univ.of Texas MD Anderson Cancer Center
  • Dr. Jean Gautier
    Professor, Columbia University Medical Center
  • Prof. Robert Sobol
    Professor of Oncologic Sciences & Chief, Molecular & Metabolic Oncology Program, University of South Alabama Mitchell Cancer Institute
  • Dr. Ralph Scully
    Associate Professor, Beth Israel Deaconess Medical Center
  • Prof. Lee Zou
    Professor, Massachusetts General Hospital

Feedback

Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr